GeneFerm Biotechnology Co Ltd
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally. The company offers microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reis… Read more
GeneFerm Biotechnology Co Ltd (1796) - Total Liabilities
Latest total liabilities as of June 2025: NT$453.10 Million TWD
Based on the latest financial reports, GeneFerm Biotechnology Co Ltd (1796) has total liabilities worth NT$453.10 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GeneFerm Biotechnology Co Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how GeneFerm Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GeneFerm Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of GeneFerm Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dynamic Group Holdings Ltd
AU:DDB
|
Australia | AU$40.85 Million |
|
Bwe Drilling Ltd
AU:BWE
|
Australia | AU$40.26 Million |
|
Sempio Foods
KO:007540
|
Korea | ₩147.64 Billion |
|
LeadDesk Oyj
HE:LEADD
|
Finland | €24.80 Million |
|
Lacroix Group SA
PA:LACR
|
France | €341.60 Million |
|
Dusk Group Limited
F:6EA
|
Germany | €54.92 Million |
|
446540
KQ:446540
|
Korea | ₩7.95 Billion |
|
Youngbo Chem
KO:014440
|
Korea | ₩20.15 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down GeneFerm Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GeneFerm Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GeneFerm Biotechnology Co Ltd (2017–2024)
The table below shows the annual total liabilities of GeneFerm Biotechnology Co Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$358.31 Million | +26.82% |
| 2023-12-31 | NT$282.54 Million | -21.27% |
| 2022-12-31 | NT$358.86 Million | -36.96% |
| 2021-12-31 | NT$569.22 Million | -2.93% |
| 2020-12-31 | NT$586.38 Million | +1174.74% |
| 2019-12-31 | NT$46.00 Million | -67.30% |
| 2018-12-31 | NT$140.69 Million | -27.40% |
| 2017-12-31 | NT$193.79 Million | -- |